EUCTR2006-003036-30-IT进行中（未招募）不适用
Prospective, randomized, observer-blind, parallel-group, multi-center trial to assess efficacy and safety of two different dilutions of NT 201 in patients with upper limb spasticity - NT-SPI
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •? Female or male patients >= 18 years
- •? Stable upper limb spasticity of diverse etiology: >= 6 months after stroke, brain injury or spinal cord injury or multiple sclerosis with no relapse within 3 month prior to screening visit or cerebral palsy
- •? Focal spasticity with >= 2 points on the Ashworth scale in the wrist flexors (incl. clinical pattern of flexed wrist) or wrist (incl. clinical pattern of flexed wrist) and elbow flexors (incl. clinical pattern of flexed elbow)
- •? Disability Assessment Scale [DAS] score >= 2 for principle therapeutic target
- •? For pre-treated patients only:
- •source documentation of the most recent injection session with botulinum toxin and sufficient therapeutic response for flexed wrist or flexed wrist and elbow
- •? For pre-treated patients only:
- •Total dose of most recent injection with botulinum toxin must have been not more than of 400 units BOTOX (1600 units Dysport or 16.000 units Neurobloc (type B)) for the affected flexors of wrist or affected flexors of wrist and elbow. For flexor carpi ulnaris, the maximal dose must have been not more than 50 units BOTOX (200 units Dysport or 2000 units Neurobloc), for flexor carpi radialis, the maximal dose must have been not more than 60 units BOTOX (240 units Dysport or 2400 units Neurobloc).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •? Previous treatment with botulinum toxin of any serotype during the last 4 months prior to screening visit
- •? Change in co-medication with centrally acting muscle relaxants (including benzodiazepines) within the 4
- •weeks prior to screening and/or co-medication with centrally acting muscle relaxants which dose cannot be kept constant during the trial
- •? Change in antidepressive medication within the 8 weeks prior to screening visit and/or antidepressive medication which dose cannot be kept constant during the trial
- •? Change in physical or occupational therapy regimens or in any other rehabilitation treatment of spasticity (including splinting) within the 4 weeks prior to screening and/or physical or occupational therapy or any other rehabilitation treatment of spasticity that cannot be kept constant during the trial
- •? Treatment with intrathecal baclofen within 4 weeks prior to screening visit
- •? Planned surgery of the target limb
- •? Surgical treatment in the target limb for any indication within 8 weeks prior to screening visit
- •? Hypersensitivity to human serum albumin, sucrose or botulinum neurotoxin type A
- •? Treatment with non-authorized concomitant medication
- •? Severe atrophy of target limb muscles
- •? Infection in the area of the planned injection points
- •? Anticoagulation therapy which requires an INR value of> 2.5
研究者
相似试验
进行中（未招募）
不适用
Prospective, randomized, observer-blind, parallel-group, multi-center trial to assess efficacy and safety of two different dilutions of NT 201 in patients with upper limb spasticity - NT-SPIEUCTR2006-003036-30-ATMerz Pharmaceuticals GmbH200
进行中（未招募）
不适用
Prospective, randomized, observer-blind, parallel-group, multi-center trial to assess efficacy and safety of two different dilutions of NT 201 in patients with upper limb spasticity - NT-SPIEUCTR2006-003036-30-DEMerz Pharmaceuticals GmbH200
进行中（未招募）
1 期
Prospective, randomized, observer-blind, parallel-group, multi-center trial to assess efficacy and safety of two different dilutions of NT 201 in patients with upper limb spasticity - NT-SPIChronic upper limb spasticity caused by diverse etiologiesMedDRA version: 9.0Level: LLTClassification code 10028335EUCTR2006-003036-30-FRMerz Pharmaceuticals GmbH200
进行中（未招募）
1 期
Prospective, randomized, observer-blind, parallel-group, multi-center trial to assess efficacy and safety of two different dilutions of NT 201 in patients with upper limb spasticity - NT-SPIChronic upper limb spasticity caused by diverse etiologiesMedDRA version: 9.0 Level: LLT Classification code 10028335EUCTR2006-003036-30-GBMerz Pharmaceuticals GmbH200
进行中（未招募）
3 期
A prospective, observer blind, randomized, parallel group, comparative, 2-arm study to evaluate the safety and efficacy of Cisatracurium Besylate Injection versus Atracurium Besylate for neuromuscular blockade in adult patients undergoing diagnostic or therapeutic surgical procedures.CTRI/2013/11/004173Themis Medicare Limited200